This double-blind, placebo-controlled trial (n=140) investigates the efficacy and safety of ketamine in rapidly reducing severe suicide risk among youth aged 14-30 who have attempted suicide.
Randomised, triple-blind, placebo-controlled parallel trial (n=140) in inpatient youth (14–30) comparing IV ketamine 0.5 mg/kg infused over 40 minutes every other day to saline; up to six infusions until clinical response or discharge.
All participants receive weekly CAMS psychotherapy starting as an inpatient and continuing outpatient; outcomes include SSI scores, suicidal attempts, readmissions and monthly follow-up for 3 months.
IV ketamine infusions plus weekly CAMS psychotherapy
0.5 mg/kg IV infusion over 40 minutes; repeat every other day up to 6 infusions or until response/discharge.
CAMS weekly psychotherapy starting inpatient and continuing outpatient.
Saline placebo infusions plus weekly CAMS psychotherapy
Saline (0.9% sodium chloride) infusion over 40 minutes as placebo comparator.
CAMS weekly psychotherapy starting inpatient and continuing outpatient.